<DOC>
	<DOCNO>NCT02097121</DOCNO>
	<brief_summary>This study evaluate safety efficacy onabotulinumtoxinA ( BOTOXÂ® ) treatment urinary incontinence due overactive bladder pediatric patient age 12 17 year adequately manage anticholinergic .</brief_summary>
	<brief_title>OnabotulinumtoxinA Treatment Urinary Incontinence Due Overactive Bladder Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Symptoms overactive bladder ( OAB ) ( frequency/urgency ) urinary incontinence least 6 month OAB symptom adequately manage 1 anticholinergic agent OAB cause neurological condition Use anticholinergic medication treat OAB symptom within 7 day Current use indwelling catheter clean intermittent catheterization empty bladder Previous current use botulinum toxin therapy serotype urological condition , treatment botulinum toxin serotype within 3 month condition use Myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>